Joshua Richter

MD, Mount Sinai, US

Specializes in [Hematology/Oncology]

ASH 2024 Oral Presentation: Presented Phase I results demonstrating cevostamab’s clinical activity and manageable safety in heavily pretreated relapsed/refractory multiple myeloma.
Co-First Author, Nature Medicine: Published research on cevostamab, an FcRH5×CD3 bispecific antibody for relapsed/refractory multiple myeloma.
Tisch Cancer Institute: Director of Clinical Research for Multiple Myeloma 2026
International Myeloma Society (IMS): Global Leadership Opportunity (GLO) 2026